← Back to Clinical Trials
Recruiting NCT06625372

Comparison of Intralipid With SMOF Lipid Following HSCT

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Leukemia
Sponsor Shahid Beheshti University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 2 Years
Max Age 18 Years
Start Date 2024-10-12
Completion 2025-08
All Conditions
Interventions
SMOF lipidINTRALIPIDS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.

Eligibility Criteria

Inclusion Criteria: * Willingness to cooperate and complete the informed consent form by the legal guardian of the child; * Age ≤ 18 years; * Definitive diagnosis of acute leukemia and candidate for hematopoietic stem ● cell transplantation; * Eligible for parenteral nutrition support; * No contraindications for parenteral nutrition; * No history of allergy to egg or soy protein; * Absence of severe organ failure or impaired liver function test (bilirubin \> 2.5 mg/dL). Exclusion Criteria: * Death of the child earlier than 5 days from the start of the intervention; * Unwillingness to continue cooperation during study; * Occurrence of side effects during the study; * In case of sepsis, hypotension, shock, thrombosis, myocardial infarction, liver dysfunction, the patient will be excluded from the study.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}